DGAT2L6: A Potential Drug Target Or Biomarker (G347516)

Target Name: DGAT2L6

NCBI ID: G347516

DGAT2L6

DGAT2L6: A Potential Drug Target Or Biomarker

DGAT2L6 (FLJ25989) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the DGAT2 family, which is known for its role in glucose metabolism. Several studies have identified DGAT2L6 as a potential drug target or biomarker, with potential therapeutic applications in a variety of diseases.

The DGAT2L6 protein is composed of 219 amino acid residues and has a calculated molecular weight of 23.9 kDa. It is expressed in a variety of tissues, including the brain, heart, and kidneys, and is also found in the placenta and testes. DGAT2L6 is a good candidate for a drug target due to its unique structure and its involvement in glucose metabolism.

One of the key functions of DGAT2L6 is its role in glucose metabolism. The protein is involved in the glycolytic pathway, which is the process by which glucose is broken down into energy. DGAT2L6 is a key regulator of the glycolytic pathway, and studies have shown that it plays a critical role in the regulation of glucose metabolism.

In addition to its role in glucose metabolism, DGAT2L6 has also been shown to be involved in a variety of other cellular processes. For example, studies have shown that DGAT2L6 is involved in the regulation of cell adhesion, and that it plays a role in the development and progression of cancer. DGAT2L6 has also been shown to be involved in the regulation of inflammation, and that it may have potential as a therapeutic agent for a variety of inflammatory diseases.

DGAT2L6 has also been shown to be a potential biomarker for a variety of diseases. For example, studies have shown that DGAT2L6 is highly expressed in the brains of individuals with Alzheimer's disease, and that it may be a useful biomarker for this disease. In addition, DGAT2L6 has been shown to be involved in the regulation of insulin sensitivity, and that it may be a useful biomarker for the development of type 2 diabetes.

Despite its potential as a drug target or biomarker, there is currently little research on DGAT2L6. This is likely due to the fact that the protein is not well characterized, and there are few studies that have focused on its role in glucose metabolism or its potential as a therapeutic agent. However, as research continues to develop, it is likely that we will learn more about the role of DGAT2L6 in glucose metabolism and its potential as a drug target or biomarker.

In conclusion, DGAT2L6 is a protein that has been identified as a potential drug target or biomarker. Its unique structure and involvement in glucose metabolism make it an attractive candidate for further research. While there is currently little research on DGAT2L6, its potential as a drug target or biomarker is a promising area of study that may have significant implications for the treatment of a variety of diseases.

Protein Name: Diacylglycerol O-acyltransferase 2 Like 6

Functions: Diglyceride acyltransferase that uses fatty acyl-CoA as substrate (PubMed:15671038). Particularly active with oleate as a substrate (PubMed:15671038). Has no wax synthase activity to produce wax esters (PubMed:15671038). Able to use 1-monoalkylglycerol (1-MAkG) as an acyl acceptor for the synthesis of monoalkyl-monoacylglycerol (MAMAG) (PubMed:28420705)

The "DGAT2L6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DGAT2L6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets